Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 78

1 992 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 992
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 992 trials in Auderghem

Open in trial search

Study on the Effects of VHB937 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:VHB937
  • Sponsor:Novartis Pharma AG

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Title: Study of solrikitug compared to placebo for adults with Eosinophilic Esophagitis to evaluate its effectiveness and safety

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Solrikitug
  • Sponsor:NI One Inc.

Colitis ulcerative

Not recruiting

Study on BI 3032950 for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 3032950
  • Sponsor:Boehringer Ingelheim International GmbH

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Alumis Inc.

Colitis ulcerative

Not recruiting

Study on GS-1427 for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GS-1427
  • Sponsor:Gilead Sciences Inc.

Study on the Safety and Effectiveness of Naronapride for Adults with Moderate Idiopathic or Diabetic Gastroparesis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Naronapride Dihydrochloride Trihydrate
  • Sponsor:Dr. Falk Pharma GmbH

A Study of Depemokimab and Prednisolone in Adults with Hypereosinophilic Syndrome (HES)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Rhinitis allergic

Not recruiting

Study of Lebrikizumab and Mometasone Furoate for Adults with Perennial Allergic Rhinitis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Hidradenitis

Not recruiting

Study on Long-term Effects of Secukinumab in Patients with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study on the Effects of SAR443765 and Mometasone Furoate in Adults with Chronic Rhinosinusitis with Nasal Polyps

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Effectiveness and Safety of Lanifibranor for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis Stages F2/F3

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lanifibranor
  • Sponsor:Inventiva

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.